Sabba Stephen L

Average Profitability
53.3%
Insider Buys Quantity
3
Insider Buys Sum
$109,230.00
Insider Sells Quantity
6
Insider Sells Sum
$2.19M

Insider Activity of Sabba Stephen L

According to the SEC Form 4 filings, Sabba Stephen L, being in a position of

  1. director at Ligand Pharmaceuticals Incorporated,
    оver the last 12 months, has bought 0 shares, and sold 1893 shares for $140,650,
    over all time since 2011-11-10, has bought 4000 shares for $109,230, and sold 15348 shares for $2.19M.

The largest purchase of all time was on 2014-10-09 and amounted to 2000 shares of Ligand Pharmaceuticals Incorporated for $86,230.

The largest sale of all time was on 2018-09-04 and amounted to 5000 shares of Ligand Pharmaceuticals Incorporated for $1.28M.

Biography of Sabba Stephen L

No biography is available at this moment.

2024-03-05SaleLigand Pharmaceuticals Incorporated
LGND
director
1,893
0.0108%
$74.30$140,650+17.52%
2023-05-10SaleLigand Pharmaceuticals Incorporated
LGND
director
6,408
0.0373%
$77.13$494,225-9.46%
2018-09-04SaleLigand Pharmaceuticals Incorporated
LGND
director
5,000
0.0233%
$255.05$1.28M-52.36%
2018-03-12SaleLigand Pharmaceuticals Incorporated
LGND
director
622
0.0029%
$180.73$112,414-7.46%
2017-12-20SaleLigand Pharmaceuticals Incorporated
LGND
director
925
0.0044%
$137.25$126,956+25.63%
2014-10-09PurchaseLigand Pharmaceuticals Incorporated
LGND
director
2,000
0.01%
$43.12$86,230+87.44%
2014-02-27SaleLigand Pharmaceuticals Incorporated
LGND
director
500
0.0025%
$72.25$36,125-22.57%
2011-11-14PurchaseLigand Pharmaceuticals Incorporated
LGND
director
1,000
0.0051%
$11.50$11,500+32.81%
2011-11-10PurchaseLigand Pharmaceuticals Incorporated
LGND
director
1,000
0.0054%
$11.50$11,500+39.65%
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.